CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.17280117

https://www.iajps.com/volumes/volume12-october-2025/10-issue-10-october-25/

Available online at: http://www.iajps.com *Review Article*

THE ROLE OF NON-INVASIVE VENTILATION IN ACUTE EXACERBATIONS OF COPD IN THE EMERGENCY SETTING: A REVIEW OF OUTCOMES AND BEST PRACTICES

[1]Ahmed Mosa Hunayshi, [2]Abdullah Mohammed Alqahtani, [3]Fahd Hamed Alsuhemi, [4]Abdo Ali Doshi, [5]Mohammed Suliman Zanim, [6]Abdulaziz Hamad Hazazi, [7]Ali Baalghayth Alkhayri, [8]Abdullah Ibrahim Aldirhami, [9]Ahmed Hussain Harthi, [10]Abdullah Mohammad Alkatheri

[1]Technician, Emergency medical services, Red Crescent Jeddah, ahmo997@gmail.com
[2]Technician, Emergency medical services, Red Crescent Jeddah, abu3aabed1234@gmail.com
[3]Technician, Emergency medical services, Red Crescent Jeddah, aboazooz1101@gmail.com
[4]Technician, Emergency medical services, Red Crescent Jeddah, abdo.doshi00@gmail.com
[5]Technician, Emergency medical services, Red Crescent Jeddah, mohdzneem@gmail.com
[6]Technician, Emergency medical services, Red Crescent Jeddah, aziz3778h@gmail.com
[7]Technician, Emergency medical services, Red Crescent Jeddah, ali0563316883@gmail.com
[8]Technician, Emergency medical services, Red Crescent Jeddah, Drabdullah520@gmail.com
[9]Technician, Emergency medical services, Red Crescent Jeddah, Harthi92@hotmail.com
[10]Technician, Emergency medical services, Red Crescent Jeddah, Aalkatheri000@gmail.com

Abstract:
Chronic Obstructive Pulmonary Disease (COPD) imposes a significant burden on healthcare systems worldwide, particularly through acute exacerbations (AECOPD), which are major contributors to emergency department (ED) visits and hospitalizations. Non-invasive ventilation (NIV) has emerged as a critical intervention for managing AECOPD, yet its implementation in the ED remains variable. This review aims to evaluate the efficacy of NIV in improving clinical outcomes for patients with AECOPD in the emergency setting, outline best practices for its initiation and monitoring, and identify barriers to its implementation. A comprehensive literature search was conducted across multiple databases to identify studies related to NIV for AECOPD in EDs. Data were synthesized thematically to summarize evidence on key outcomes, including mortality, intubation rates, and hospital length of stay. Evidence consistently supports the use of NIV in reducing mortality and intubation rates among patients with AECOPD. Effective patient selection, timely initiation, and adequate monitoring are essential for maximizing the benefits of NIV. However, barriers such as resource limitations, staff training deficiencies, and workflow integration challenges hinder widespread adoption. NIV represents a life-saving therapy for patients with AECOPD in the ED. By addressing identified barriers and implementing standardized protocols, healthcare systems can enhance the delivery of NIV, ultimately improving patient outcomes and reducing the burden of COPD exacerbations.

Keywords: *Non-invasive ventilation, Chronic Obstructive Pulmonary Disease, Acute exacerbations, Emergency department, Patient outcomes.*

Corresponding author:
Ahmed Mosa Hunayshi,
ahmo997@gmail.com

Please cite this article in press ***Ahmed Mosa Hunayshi*** *et al.,* ***The Role Of Non-Invasive Ventilation In Acute Exacerbations Of Copd In The Emergency Setting: A Review Of Outcomes And Best Practices****, Indo Am. J. P. Sci, 2025; 12(10).*

1. INTRODUCTION:

1.1.The Global Burden of COPD and Acute Exacerbations

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, with a profound impact on healthcare systems. A significant portion of the disease's burden stems from Acute Exacerbations of COPD (AECOPD), which are characterized by a sudden worsening of respiratory symptoms. These events are major drivers of emergency department (ED) visits, hospital admissions, and mortality (Crisafulli et al., 2018). In the United States alone, AECOPD account for over 1.5 million ED visits annually, placing immense strain on acute care resources (Pappas & Vempati, 2023). Exacerbations are frequently triggered by respiratory infections and environmental pollutants, leading to increased airway inflammation, bronchoconstriction, and dynamic hyperinflation.

1.2. Pathophysiology of Respiratory Failure in AECOPD

The progression from a stable COPD state to acute respiratory failure during an exacerbation is driven by a cascade of physiological derangements. Increased airway resistance and loss of elastic recoil significantly elevate the work of breathing. This leads to respiratory muscle fatigue and a consequent reduction in minute ventilation, resulting in carbon dioxide (CO2) retention and respiratory acidosis (Ambrosino & Vagheggini, 2007). The resulting hypercapnia and hypoxemia, if untreated, create a vicious cycle that can rapidly progress to respiratory arrest. Conventional management with controlled oxygen therapy, bronchodilators, and corticosteroids addresses some components but does not directly support the failing respiratory muscles or correct hypercapnia, creating a critical therapeutic gap for a significant subset of patients.

1.3.The Emergency Department as the Critical Intervention Point

The ED serves as the frontline for managing severe AECOPD, making it a crucial environment for initiating life-saving interventions. The early period following presentation is a pivotal window where appropriate management can alter the clinical trajectory, preventing the need for invasive procedures and intensive care unit (ICU) admission (Lane et al., 2018; Moxon & Lee, 2015). However, the traditional approach of relying solely on pharmacotherapy often proves insufficient for patients presenting with acute hypercapnic respiratory failure, highlighting the need for more advanced respiratory support directly within the emergency setting.

1.4. Non-Invasive Ventilation: A Paradigm Shift in Management

The advent of Non-Invasive Ventilation (NIV) has revolutionized the management of AECOPD, establishing itself as a cornerstone of therapy. By providing positive pressure ventilation through a mask interface, NIV effectively unloads the respiratory muscles, reduces work of breathing, and improves alveolar ventilation, thereby correcting gas exchange abnormalities (Brochard, 2000). The landmark study by Plant et al. (2000) demonstrated that early administration of NIV on general respiratory wards significantly reduced the need for intubation and decreased mortality. This evidence solidified NIV not just as an alternative, but as a new standard of care for selected patients, fundamentally shifting treatment away from the inevitable progression to invasive mechanical ventilation.

Subsequent large-scale observational studies have consistently reinforced these benefits, showing that NIV is associated with lower mortality, reduced intubation rates, and shorter hospital stays compared to invasive ventilation or medical therapy alone (Lindenauer et al., 2014; Stefan et al., 2015). Despite its proven efficacy, the real-world application of NIV in the ED is variable, with challenges in patient selection, timely initiation, and staff training influencing outcomes (Elshof et al., 2023; Rose & Gerdtz, 2009).

1.5.Objectives and Scope of the Review

This review aims to synthesize the current evidence on the role of NIV in the emergency management of AECOPD. Specifically, it will:

1. To synthesize the evidence on the efficacy of NIV in improving key outcomes for AECOPD patients in the ED.
2. To outline evidence-based best practices for the initiation, monitoring, and weaning of NIV in the emergency setting.
3. To identify barriers to implementation and future directions.

2. METHODS:

2.1. Literature Search Strategy

A comprehensive literature search was conducted to identify all relevant studies investigating the use of non-invasive ventilation (NIV) for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in the emergency setting.

- Information Sources: The following electronic databases were systematically searched from their inception: PubMed/MEDLINE, Embase (via Elsevier), the Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus.
- Search Strategy: The search strategy utilized a combination of Medical Subject Headings (MeSH) and free-text keywords to capture the core concepts of the review. The primary search terms were:
  - ("Non-Invasive Ventilation" OR "NIV" OR "BiPAP" OR "Bilevel Positive Airway Pressure" OR "CPAP")
  - AND ("Chronic Obstructive Pulmonary Disease" OR "COPD" OR "COAD")
  - AND ("Acute Exacerbation" OR "Exacerbation" OR "Respiratory Failure")
  - AND ("Emergency Department" OR "ED" OR "Emergency Room" OR "ER" OR "Emergency Service" OR "Critical Care" OR "Acute Care") Boolean operators (AND, OR) were used to combine these terms, and the search was adapted for the syntax of each database.
- Time Frame and Inclusion Criteria: No initial date restrictions were applied to ensure a comprehensive historical overview. The search was limited to studies published in the English language that involved human subjects.

2.2.Study Selection and Eligibility Criteria

The study selection process adhered to a pre-defined PICOS (Population, Intervention, Comparator, Outcomes, Study Design) framework. To capture a robust evidence base, we included:

- Randomized Controlled Trials (RCTs)
- Systematic Reviews and Meta-Analyses
- Prospective and Retrospective Observational Cohort Studies Editorials, narrative reviews without original data, case reports, and conference abstracts were excluded.

❖ **Patient Population:**

The review focused on studies involving adult patients (≥18 years) presenting to an emergency department or equivalent acute care setting with a primary diagnosis of AECOPD and evidence of acute hypercapnic respiratory failure, typically defined by arterial blood gas parameters (e.g., pH < 7.35 and $PaCO_2$ > 45 mmHg).

❖ **Intervention:**

- The intervention of interest was the application of NIV (including Bilevel Positive Airway Pressure - BiPAP or Continuous Positive Airway Pressure - CPAP) initiated in the emergency setting or within the first 24 hours of hospitalization following an ED presentation.

2.3.Data Extraction and Synthesis

2.3.1. Data Extraction:

Data from the included studies were systematically extracted by one reviewer and verified by a second using a standardized data extraction form. The extracted information included:

- Study characteristics: first author, publication year, country, and study design.
- Patient demographics and sample size.
- Details of the NIV protocol (settings, interface, duration).
- Comparator group details (standard medical therapy, invasive ventilation).
- Relevant results for all pre-specified outcome measures.
-

2.3.2. Data Synthesis:

Given the anticipated heterogeneity in study designs, populations, and reported outcomes, a formal meta-analysis was not feasible. Therefore, a narrative synthesis approach was employed. The findings were organized thematically to summarize the evidence on:

1. The efficacy of NIV on key clinical outcomes (mortality, intubation).
2. Best practices regarding protocols for initiation, monitoring, and weaning.
3. Factors influencing the implementation of NIV in the emergency setting, including barriers and facilitators. This structured narrative provides a comprehensive overview of the current state of evidence and clinical practice.

3. RESULTS:

The efficacy of Non-Invasive Ventilation (NIV) in the management of Acute Exacerbations of COPD (AECOPD) is supported by a robust body of evidence spanning from landmark randomized controlled trials to large-scale real-world analyses. The benefits are multifaceted, impacting mortality, intubation rates, physiological recovery, and healthcare resource utilization.

3.1.Mortality Reduction

The most significant impact of NIV is its demonstrable effect on reducing short-term mortality. The foundational multicenter RCT by Plant et al. (2000) established this, showing a 50% relative reduction in mortality (10% in the NIV group vs. 20% in the standard therapy group) for patients with acute respiratory failure treated on general wards. This pivotal finding was later confirmed in a larger, real-world context by Lindenauer et al. (2014), whose analysis of over 25,000 U.S. hospitalizations revealed that patients initially treated with NIV had significantly lower in-hospital mortality compared to those treated with invasive mechanical ventilation. A Cochrane systematic review, which synthesizes data from multiple RCTs, has consistently reinforced this conclusion, stating that NIV reduces mortality by approximately 50% in patients with AECOPD and acute respiratory failure (Osadnik et al., 2017). This collective evidence firmly establishes NIV as a life-saving intervention.

3.2.Intubation Rate and Its Implications

A primary goal of NIV is to avert the need for invasive mechanical intubation, and the evidence for its success in this domain is compelling. The study by Plant et al. (2000) showed a near halving of the intubation rate. The implications of avoiding intubation are profound. Stefan et al. (2015) directly compared outcomes in critically ill patients and found that those treated with NIV had significantly lower rates of complications, including a drastically reduced incidence of ventilator-associated pneumonia (VAP)—a serious infection that significantly increases mortality, ICU length of stay, and healthcare costs. By preventing intubation, NIV also avoids the associated risks of airway trauma, sedation-related complications, and difficulty in weaning, leading to improved overall patient outcomes and reduced long-term morbidity (Bourke et al., 2018).

3.3.Improvement in Physiological Parameters

The clinical benefits of NIV are rooted in its rapid correction of the underlying pathophysiology of AECOPD. Studies consistently show a swift and significant improvement in key physiological parameters within the first few hours of initiation.

1. **Gas Exchange:**

NIV directly addresses hypercapnic respiratory failure by providing ventilatory support. This leads to a marked reduction in arterial partial pressure of carbon dioxide ($PaCO_2$) and a corresponding correction of acidosis (rise in pH), often observed within the first 1-2 hours of treatment (**Brochard, 2000; Ambrosino & Vagheggini, 2007**).

2. **Vital Signs and Symptoms:**

As respiratory muscle workload decreases, patients experience a rapid reduction in respiratory rate and heart rate. Concurrently, dyspnea scores improve significantly, providing subjective relief to the distressed patient (**Moxon & Lee, 2015; Crisafulli et al., 2018**). This rapid physiological turnaround is a key indicator of NIV success and can often prevent further clinical deterioration.

3.4.Impact on Hospital Length of Stay and Healthcare Costs

The clinical efficiencies gained through NIV translate directly into significant economic benefits for healthcare systems. By preventing ICU admissions and simplifying patient management, NIV has been shown to substantially reduce hospital length of stay (LOS). Lindenauer et al. (2014) found that patients treated with NIV had a shorter median LOS compared to those who were intubated. The early initiation of NIV in the ED, as emphasized by Rose & Gerdtz (2009) and Lane et al. (2018), is a critical factor in this process, as it streamlines the care pathway, potentially allowing for management in a step-down unit or even a general ward instead of the ICU.

The economic advantage is clear. The cost savings are driven by multiple factors: the avoidance of expensive ICU bed days, the reduced need for costly invasive procedures and their associated complications (e.g., treating VAP), and the shorter overall hospitalization. A formal cost-effectiveness analysis has demonstrated that NIV is not only clinically superior but also a cost-saving strategy for managing AECOPD with respiratory failure, making it a cornerstone of high-value care in respiratory medicine (Cheung et al., 2010).

4. DISCUSSION:

The robust evidence synthesized in this review unequivocally establishes non-invasive ventilation (NIV) as a foundational therapy for acute hypercapnic respiratory failure secondary to AECOPD in the emergency setting, demonstrating consistent and significant improvements in survival, intubation rates, and key healthcare metrics. However, the translation of this high-level evidence into consistently successful patient outcomes is not automatic; it is entirely contingent upon a disciplined, protocol-driven approach to its clinical application and a clear-eyed understanding of the

challenges inherent in the emergency department environment. This discussion will therefore interpret the findings within a practical clinical framework, outlining the best practices for implementation, analyzing the barriers to widespread adoption, and exploring the evolving future applications of NIV.

4.1.Synthesis of Evidence and Clinical Implications

The successful application of Non-Invasive Ventilation (NIV) in the emergency department requires a systematic approach that balances therapeutic urgency with clinical precision (Rose & Gerdtz, 2009**).** The following best practices synthesize current evidence and expert consensus to guide emergency clinicians in optimizing patient outcomes while avoiding potential complications.

4.1.1. Patient Selection: Who is a Candidate?

Appropriate patient selection remains the cornerstone of successful NIV implementation, as improper patient selection remains a significant barrier to effective treatment (Elshof et al., 2023). The decision should integrate clinical presentation with arterial blood gas (ABG) analysis to identify patients most likely to benefit.

Research consistently identifies patients with specific characteristics as most likely to benefit from NIV. The pivotal study by Plant et al. (2000) established that patients with respiratory acidosis, defined by arterial pH between 7.25 and 7.35 accompanied by elevated $PaCO_2$ (>45 mmHg), derive significant benefit from NIV. These patients typically exhibit moderate to severe respiratory distress with clinical signs of increased work of breathing, including accessory muscle use and tachypnea (respiratory rate > 24-25 breaths/minute) **(**Crisafulli et al., 2018**).** This patient profile represents the optimal target population in whom NIV can most effectively prevent intubation.

Recognizing absolute and relative contraindications is equally crucial for patient safety. Bersten (2011) and Pappas & Vempati (2023) clearly delineate absolute contraindications including cardiorespiratory arrest, inability to protect the airway, and significant facial trauma preventing proper mask fit. Relative contraindications requiring careful risk-benefit analysis include hemodynamic instability, severe agitation, uncontrollable secretions, and undrained pneumothorax (Ambrosino & Vagheggini, 2007). In these scenarios, clinicians must weigh potential benefits against risks while maintaining readiness for rapid intubation.

4.1.2. Practical Setup and Initiation

Efficient NIV initiation in the ED requires a standardized, protocol-driven approach to ensure timely intervention and maximize therapeutic efficacy.

The oronasal (full-face) mask represents the first-line interface in acute settings according to Rose & Gerdtz (2009), as it minimizes air leaks in mouth-breathing patients and is generally better tolerated during severe dyspnea. Proper fitting is essential to balance effective seal with prevention of pressure-induced skin injury, which represents a common complication in prolonged NIV use.

For bilevel positive airway pressure (BiPAP), Moxon & Lee (2015) recommend starting with Expiratory Positive Airway Pressure (EPAP) of 4-5 cm H_2O to counteract auto-PEEP and stent airways, combined with Inspiratory Positive Airway Pressure (IPAP) of 8-10 cm H_2O. This creates initial pressure support of 4-6 cm H_2O, which can be titrated upward to achieve clinical improvement in work of breathing and adequate tidal volume (6-8 mL/kg ideal body weight). Trethewey et al. (2018) note that IPAP rarely needs to exceed 20-25 cm H_2O in the initial ED management. A backup rate of 12-16 breaths/minute provides safety in case of apnea, while FiO_2 should be titrated to maintain oxygen saturation at 88-92%, consistent with COPD management guidelines (Parums, 2023).

Successful NIV implementation requires more than equipment alone. Rose & Gerdtz (2009) emphasize the necessity of a dedicated clinical space with continuous monitoring capabilities and the presence of trained nursing and respiratory therapy staff for patient coaching, continuous assessment, and rapid troubleshooting. This team approach is essential for managing the complex needs of patients requiring NIV.

4.1.3. Monitoring, Troubleshooting, and Weaning

Vigilant monitoring and proactive management are essential throughout NIV therapy to ensure ongoing effectiveness and patient safety.

Continuous assessment should include clinical status, vital signs, and oxygen saturation. Brochard (2000) demonstrated that objective improvement should be confirmed with repeat ABG within 1-2 hours of initiation, with successful response indicated by improving pH and decreasing $PaCO_2$. Plant et al. (2001) further established that early physiological improvement predicts successful NIV outcomes, highlighting the importance of timely monitoring.

Common issues include mask discomfort, air leaks, claustrophobia, and aerophagia. Bersten (2011) outlines management strategies involving careful mask refitting, patient reassurance, temporary mask removal, and pressure adjustment. Skin protection with appropriate dressings at

pressure points is essential to prevent facial tissue injury, particularly during prolonged use.

Once clinical stability is achieved, weaning can commence through progressive reduction of NIV duration. Crisafulli et al. (2018**)** recommend alternating NIV with periods of conventional oxygen therapy while continuously monitoring for signs of deterioration. Successful weaning is typically characterized by maintained pH >7.35, decreased respiratory rate, and patient comfort on minimal ventilatory support.

4.1.4. Recognizing NIV Failure

Timely identification of NIV failure is critical to prevent dangerous delays in necessary intubation and ensure patient safety.

Bourke et al. (2018) emphasize that worsening or failure to improve respiratory distress, tachypnea, or mental status within the first 1-2 hours of treatment should raise concern. Persistent or worsening respiratory acidosis (pH <7.25 or declining despite treatment) represents the most objective indicator of NIV failure (Stefan et al., 2015). Additional warning signs include hemodynamic instability and inability to manage secretions, which may necessitate alternative management strategies.

The absence of clear clinical and biochemical improvement within the initial hours of NIV should trigger immediate preparation for endotracheal intubation. Lindenauer et al. (2014) demonstrated that delayed intubation in patients failing NIV is associated with increased mortality. Continuing NIV in the face of clear failure only increases the risk of adverse outcomes, as emphasized in the Cochrane review by Osadnik et al. (2017)**.** Establishing institutional protocols with clear failure criteria ensures appropriate and timely escalation of care, potentially improving patient outcomes.

4.2.Challenges, Barriers, and Future Directions

Despite robust evidence supporting its use, the implementation of Non-Invasive Ventilation (NIV) in emergency departments faces significant practical challenges. Furthermore, the evolving landscape of respiratory support presents new opportunities and questions regarding its optimal application.

4.2.1. Resource Limitations:

The availability and cost of NIV equipment can be a prohibitive factor, particularly in resource-limited or community hospital settings (Trethewey et al., 2018). A sufficient number of ventilators and a variety of mask interfaces must be readily available to accommodate the unpredictable volume of AECOPD presentations, which can strain departmental resources.

4.2.2. Staffing and Training Requirements:

Effective NIV management demands a skilled, multidisciplinary team. Rose & Gerdtz (2009) emphasize that successful outcomes depend not only on physician knowledge but also on the competency of nursing and respiratory therapy staff in patient coaching, mask fitting, and troubleshooting complications. A lack of trained staff, especially outside of day-shift hours, represents a critical barrier to safe and effective NIV delivery (Elshof et al., 2023**).**

4.2.3. Workflow Integration:

The high-acuity, fast-paced nature of the ED creates inherent challenges for NIV, which requires dedicated time for initiation and continuous monitoring. Integrating these resource-intensive activities without disrupting the flow of other critically ill patients is a significant operational hurdle. Without clear protocols and designated clinical spaces, NIV application can be inconsistent and delayed (Moxon & Lee, 2015**).**

4.3.Future Directions and Research Gaps

Moving beyond traditional applications, several emerging areas are shaping the future role of NIV in emergency care.

4.3.1. Palliative Care and "Do-Not-Intubate" Patients:

NIV is increasingly used in the ED as a palliative tool to alleviate dyspnea for patients with AECOPD who have a "do-not-intubate" (DNI) status. In this context, the goal shifts from preventing intubation to providing comfort, and its use requires careful patient selection and clear communication about goals of care (Bourke et al., 2018**).**

4.3.2. The Role of High-Flow Nasal Cannula (HFNC):

The role of High-Flow Nasal Cannula (HFNC) therapy in AECOPD is still being defined. While NIV remains first-line for hypercapnic respiratory failure, HFNC may serve as a better-tolerated alternative for patients who cannot tolerate NIV interfaces or as a step-down therapy after initial improvement. Crisafulli et al. (2018) note that further research is needed to clarify its precise place in the treatment hierarchy.

4.3.3. Telemedicine and Protocol-Driven Care:

To support community EDs with limited resources, telemedicine consultations and standardized, protocol-driven order sets show promise. These tools can provide remote expert guidance and ensure adherence to best practices, thereby improving the quality of NIV care across diverse healthcare settings (Schmitt et al., 2022**).**

4.3.4. Research Gaps:

Several key areas warrant further investigation. Future research should focus on identifying biomarkers to predict NIV success or failure early in the clinical course. Additionally, the development of automated algorithms to optimize ventilator settings in real-time could minimize operator-dependent variability and improve patient outcomes (Ergan et al., 2019). Exploring the pre-hospital initiation of NIV by emergency medical services, as investigated by Schmitt et al. (2022), represents another frontier for improving the continuum of care for AECOPD patients.

5. CONCLUSION:

The evidence unequivocally establishes Non-Invasive Ventilation (NIV) as a first-line, life-saving therapy for patients presenting to the emergency department with Acute Exacerbations of COPD (AECOPD) and acute hypercapnic respiratory failure. Robust data from landmark clinical trials and large-scale observational studies demonstrate that timely NIV application significantly reduces mortality, intubation rates, and hospital length of stay, solidifying its role as a cornerstone of emergency respiratory care **(**Plant et al., 2000; Lindenauer et al., 2014).

However, the efficacy of this powerful intervention is entirely dependent on its correct application. Its success hinges not on the technology itself, but on a systematic clinical approach encompassing three critical pillars: the careful selection of appropriate candidates based on clinical and blood gas criteria, the proper technical execution involving correct interface fitting and ventilator settings, and vigilant monitoring for both improvement and signs of failure **(**Brochard, 2000; Bourke et al., 2018). Without this disciplined methodology, the full benefits of NIV cannot be realized.

Therefore, a concerted call to action is imperative. To consistently improve patient outcomes and reduce the substantial burden of COPD exacerbations, healthcare institutions must prioritize the standardization of NIV care in the emergency setting. This involves the implementation of structured protocols, dedicated equipment, and ongoing, multidisciplinary training for emergency physicians, nurses, and respiratory therapists. By embedding these evidence-based practices into the core workflow of the ED, we can ensure that this life-saving therapy reaches every eligible patient effectively and safely, ultimately fulfilling its potential to transform the emergency management of severe COPD.

REFERENCES:

1. Ambrosino, N., & Vagheggini, G. (2007). Non-invasive ventilation in exacerbations of COPD. *International journal of chronic obstructive pulmonary disease*, *2*(4), 471-476.
2. Bersten, A. D. (2011). Best practices for noninvasive ventilation. *CMAJ*, *183*(3), 293-294.
3. Bourke, S. C., Piraino, T., Pisani, L., Brochard, L., & Elliott, M. W. (2018). Beyond the guidelines for non-invasive ventilation in acute respiratory failure: implications for practice. *The Lancet Respiratory Medicine*, *6*(12), 935-947.
4. Brochard, L. (2000). Non-invasive ventilation for acute exacerbations of COPD: a new standard of care. *Thorax*, *55*(10), 817-818.
5. Crisafulli, E., Barbeta, E., Ielpo, A., & Torres, A. (2018). Management of severe acute exacerbations of COPD: an updated narrative review. *Multidisciplinary respiratory medicine*, *13*(1), 36.
6. Elshof, J., Vonk, J. M., van der Pouw, A., van Dijk, C., Vos, P., Kerstjens, H. A., ... & Duiverman, M. L. (2023). Clinical practice of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *Respiratory Research*, *24*(1), 208.
7. Ergan, B., Oczkowski, S., Rochwerg, B., Carlucci, A., Chatwin, M., Clini, E., ... & Windisch, W. (2019). European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. *European respiratory journal*, *54*(3).
8. Lane, N. D., Brewin, K., Hartley, T. M., Gray, W. K., Burgess, M., Steer, J., & Bourke, S. C. (2018). Specialist emergency care and COPD outcomes. *BMJ Open Respiratory Research*, *5*(1).
9. Lindenauer, P. K., Stefan, M. S., Shieh, M. S., Pekow, P. S., Rothberg, M. B., & Hill, N. S. (2014). Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease. *JAMA internal medicine*, *174*(12), 1982-1993.
10. Moxon, A., & Lee, G. (2015). Non-invasive ventilation in the emergency department for patients in type II respiratory failure due to COPD exacerbations. *International emergency nursing*, *23*(3), 232-236.
11. Osadnik, C. R., Tee, V. S., Carson-Chahhoud, K. V., Picot, J., Wedzicha, J. A., & Smith, B. J. (2017). Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. *Cochrane database of systematic reviews*, (7).
12. Pappas, D., & Vempati, A. (2023). Acute Exacerbation of COPD. *Journal of education & teaching in emergency medicine*, *8*(2), S35.
13. Parums, D. V. (2023). global initiative for chronic obstructive lung disease (GOLD) 2023

guidelines for COPD, including COVID-19, climate change, and air pollution. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, *29*, e942672-1.

14. Plant, P. K., Owen, J. L., & Elliott, M. W. (2000). Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. *The Lancet*, *355*(9219), 1931-1935.
15. Plant, P. K., Owen, J. L., & Elliott, M. W. (2001). Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. *Thorax*, *56*(9), 708-712.
16. Rose, L., & Gerdtz, M. F. (2009). Review of non-invasive ventilation in the emergency department: clinical considerations and management priorities. *Journal of clinical nursing*, *18*(23), 3216-3224.
17. Schmitt, F. C., Gruneberg, D., Schneider, N. R., Fögeling, J. O., Leucht, M., Herth, F., ... & Popp, E. (2022). Non-invasive ventilation as a therapy option for acute exacerbations of chronic obstructive pulmonary disease and acute cardiopulmonary oedema in emergency medical services. *Journal of clinical medicine*, *11*(9), 2504.
18. Stefan, M. S., Nathanson, B. H., Higgins, T. L., Steingrub, J. S., Lagu, T., Rothberg, M. B., & Lindenauer, P. K. (2015). Comparative effectiveness of noninvasive and invasive ventilation in critically ill patients with acute exacerbation of chronic obstructive pulmonary disease. *Critical care medicine*, *43*(7), 1386-1394.
19. Trethewey, S. P., Edgar, R. G., Turner, A. M., & Mukherjee, R. (2018, December). Ward-based non-invasive ventilation in acute exacerbations of COPD: a narrative review of current practice and outcomes in the UK. In *Healthcare* (Vol. 6, No. 4, p. 145). MDPI.